The retinoblastoma protein (pRB) is encoded by the RB1 gene whose promoter contains several putative binding sites for ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa), a transcriptional regulator of the topoisomerase IIa gene. ICBP90 has two consensus binding sites for pRB in its primary sequence. Here, we show that pRB and ICBP90 co-immunoprecipitate in cell extracts of proliferating human lung fibroblasts and of proliferating or confluent Jurkat cells. GST pull-down assays and immunocytochemistry, after cell synchronization in late G1 phase, confirmed this interaction. Overexpression of ICBP90 induces downregulation of pRB expression in lung fibroblasts as a result of mRNA decrease. DNA chromatin immunoprecipitation experiment shows that ICBP90 binds to the RB1 gene promoter under its methylated status. Overexpression of ICBP90 increases the S and G2/M phase cell fractions of serum-starved lung fibroblasts as assessed by flow cytometry analysis and increases topoisomerase IIa expression. Together, these results show that ICBP90 regulates pRB at the protein and gene transcription levels, thus favoring the entry into the S phase of the cells. We propose that ICBP90 overexpression, found in cancer cells, is involved in the altered checkpoint controls occurring in cancerogenesis. Oncogene (2005) 24, 7337-7345.
The retinoblastoma protein (pRB) is encoded by the RB1 gene whose promoter contains several putative binding sites for ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa), a transcriptional regulator of the topoisomerase IIa gene. ICBP90 has two consensus binding sites for pRB in its primary sequence. Here, we show that pRB and ICBP90 co-immunoprecipitate in cell extracts of proliferating human lung fibroblasts and of proliferating or confluent Jurkat cells. GST pull-down assays and immunocytochemistry, after cell synchronization in late G1 phase, confirmed this interaction. Overexpression of ICBP90 induces downregulation of pRB expression in lung fibroblasts as a result of mRNA decrease. DNA chromatin immunoprecipitation experiment shows that ICBP90 binds to the RB1 gene promoter under its methylated status. Overexpression of ICBP90 increases the S and G2/M phase cell fractions of serum-starved lung fibroblasts as assessed by flow cytometry analysis and increases topoisomerase IIa expression. Together, these results show that ICBP90 regulates pRB at the protein and gene transcription levels, thus favoring the entry intoIntroduction Deregulation of genes that are involved in the progression from G1 to S phase of the cell cycle is a frequent event in numerous tumor types, including lung cancer (Betticher et al., 1997) , melanoma (Walker et al., 1998) , pituitary adenomas (Simpson et al., 2001 ) and esophageal carcinoma (Roncalli et al., 1998) . Among these genes, the tumor-suppressor RB1 gene, encoding the 928-amino-acid long nuclear protein pRB, is of extreme importance. Indeed, pRB expression or activity loss has been found in a plethora of human cancers as a result of gene deletion, promoter hypermethylation, point mutation, deregulated phosphorylation or sequestration by oncoproteins (Simpson et al., 2000; Strobeck et al., 2000a, b; Nakamura et al., 2001; Angus et al., 2002; Gonzalez-Gomez et al., 2003) .
The RB1 gene functions to suppress tumorigenesis by inhibiting cell cycle progression at the G1/S transition through the repression of several genes (Kaelin, 1997 (Kaelin, , 1999 Hickman et al., 2002) . Indeed, reintroduction of a functional pRB gene in pRB-defective cells blocks tumor cells entry into S phase (Kaelin, 1997) . Two mechanisms appear to be involved in the gene transcription repression mechanism by pRB. One of them involves an interaction of pRB with the members of the E2F transcription factors family and mediates repression of E2F-regulated genes (Dyson, 1998; Zhang et al., 1999) . However, it seems that only those involved in apoptosis are targeted by pRB (Young and Longmore, 2004) . The second mechanism implicates a recently described protein complex that includes gene products involved in the epigenetic regulation of cell differentiation (Zhang and Dean, 2001 ). Indeed, it was shown that pRB interacts with Dnmt1 and by this way plays a role in permanent DNA methylation (Pradhan and Kim, 2002) . Furthermore, pRB cooperates with SUV39H1 and HP1 in order to repress the cyclin E promoter by a mechanism involving histone H3 methylation, suggesting that the SUV39H1-HP1 complex is also involved in repression of euchromatic genes by pRb (Nielsen et al., 2001) .
pRB is hypophosphorylated in G0/G1 phases and becomes overtly hyperphosphorylated at or near the G1/S boundary (Kaelin, 1999) . Hyperphosphorylation of pRB by cyclin-dependent kinases and downregulation of pRB is associated with cell proliferation, particularly with S-phase entry (Almasan et al., 1995; Kaelin, 1999) , whereas differentiation correlates with RB1 mRNA accumulation (Coppola et al, 1990; Endo and Goto, 1992; Richon et al., 1992; Slack et al., 1993; Chen et al., 1996) . Although some negative regulators of the pRB expression have been identified, such as BRCA1 and p16
INK4A (Fang et al., 1998; Fan et al., 2001) , not much is known about the proteins involved in RB1 gene repression.
We have recently found that ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa), a transcription factor involved in the topoisomerase IIa gene expression (Hopfner et al., 2000) , has a cell cycle-dependent expression in noncancer cells, with a major peak in late G1, whereas it exhibits a permanent and constant cell cycle expression in cancer cells (Mousli et al., 2003) . ICBP90 exerts its transcriptional activity through the binding of a DNA sequence containing the CCAAT motif (Hopfner et al., 2000) . This binding is regulated by phosphorylation via protein kinase A (Trotzier et al., 2004) . However, the binding of ICBP90 to the promoters of p16
INK4A and p14 ARF as well as of RARb is methylation dependent, suggesting that ICBP90 has also affinity for CpG islands (Unoki et al., 2004) . Several CCAAT boxes, some of which are in the inverted orientation, and CpG islands are present in the RB1 gene promoter (Figure 1a ). Beside its ability to bind DNA, ICBP90 probably plays an important role in chromatin remodeling through protein/protein interactions. Indeed, the G9a/SRA domain of ICBP90 (see localization in Figure 1b ) is responsible for the interaction with HDAC1 (Unoki et al., 2004) , known to play a repressive role in gene expression by a chromatin remodeling activity via deacetylation of histones (Wade, 2001) . Also Np95, a murine homolog of ICBP90, has H3 ubiquitination activity and belongs to the E3 ligase family (Citterio et al., 2004) . Ubiquitination of histones plays a fundamental role in chromatin structure and therefore in the transcription of several genes (Zhang, 2003) .
Consequently, considering that two consensus pRB binding sites (LXCXE) exist in the ICBP90 primary sequence (Figure 1b ) and the structure of the RB1 gene promoter, we hypothesized that ICBP90 regulates pRB at two levels, that is, at the RB1 transcription level and the protein level. In the present study, we show that pRB and ICBP90 co-immunoprecipitate and that overexpression of ICBP90 downregulates pRB expression. We suggest that this dual action of ICBP90 on pRB functions is a key mechanism of S-phase entry and that the higher expression of ICBP90 found in cancer cells is involved in permanent cell cycling. Furthermore, we speculate that ICBP90 is the protein that targets pRB and other actors of the epigenetic code to the gene promoters to establish gene repression.
Results

Relevance of the investigation of ICBP90 as a putative pRB regulator
A schematical representation of the RB1 gene promoter and the primary structure of the ICBP90, ICBP52 and Figure 1 Schematical representation of the RB1 gene promoter (a) and structural domains of ICBP90 and NIRF (b) . This representation is based on the nucleotide sequence of genomic DNA deposited in Genbank under the Accession number AL392048. Bases are numbered with respect to the first transcription start site designated as þ 1 and base numbers refer to the 5 0 -end of each element. The three transcription start sites are shown by bent arrows and are those described by Hong et al. (1989) . Putative regulatory elements such as CCAAT boxes (CB1, CB2), CCAAT boxes in the inverted orientation (Inverted CCAAT boxes, ICB1-ICB4) and GC-rich elements (GC), that is, putative binding sites for Sp1 are depicted. Blank arrows indicate the positions of the primers used in the ChIP experiments. Structural domains of ICBP90, ICBP52 and NIRF correspond to amino-acid positions and putative consensus pRB binding sites are indicated (RB). The ubiquitin-like domain (UBQ), the two zinc-finger domains (PHD, RING) and the G9a domain (G9/SRA) are indicated. Nt and Ct show the orientation of the proteins from the N-terminal toward the C-terminal part, respectively. The asterisk indicates the position of the frame shift found in ICBP52 resulting in the deletion of the RING finger ICBP90 regulates pRB expression M Jeanblanc et al NIRF are shown in Figure 1 . The RB1 gene promoter is characterized by the presence of two CCAAT Boxes (CB1 and CB2) as well as by the presence of four CCAAT boxes in the inverted orientation (ICB1 to ICB4) ( Figure 1a ). Considering that ICBP90 has CCAAT box binding properties (Hopfner et al., 2000) , all the CCAAT sequences, whatever the orientation, are putative ICBP90 binding sites and make the RB1 gene promoter as a potential target for ICBP90 transcriptional regulation. GC-rich boxes are represented considering that they are privileged target for methylation (Momparler, 2003) and that ICBP90 has affinity for methylated promoters through its G9a/SRA domain (Unoki et al., 2004) . Figure 1b shows that ICBP90 has two pRB consensus binding sites, both located in zincfinger domains, that is, in the PHD as well as in the RING domain. ICBP52, lacking the ubiquitin-like and the RING domains only exhibit one putative pRB binding site, that is, that located in the PHD domain. The pRB binding site in the RING finger of NIRF is lacking.
Interaction of ICBP90 with the product of the RB1 gene
To investigate the link between ICBP90 and pRB, we analysed the expression patterns of ICBP90 and pRB in human lung fibroblasts and Jurkat cells under proliferating and confluence conditions with or without immunoprecipitation ( Figure 2 ). Expression of Ki-67, a nuclear proliferation marker, was investigated in order to check the cell cycle status of the cells and the specificity of the co-immunoprecipitation. The expression pattern of Ki-67 confirmed that fibroblasts have left the cell cycle at confluence, whereas Jurkat cells did not ( Figure 2a) . A similar expression pattern was obtained with the topoisomerase IIa further confirming the cell status of the fibroblasts and Jurkat cells (data not shown). Fibroblasts and Jurkat cells, both at confluence mainly contained the hypophosphorylated form of pRB (110 kDa), whereas during proliferation, the hyperphosphorylated form (114 kDa) was the major form. ICBP90 is not expressed in fibroblasts at confluence, whereas it appeared when cells are proliferating ( Figure 2a ). In contrast, in Jurkat cells, ICBP90 is expressed at the proliferating and confluence states ( Figure 2a ). Immunoprecipitation of ICBP90 with the anti-ICBP90 mAb showed no band for pRB in confluent fibroblasts, whereas a slight band was observed for proliferating cells (Figure 2a ). In contrast, in confluent Jurkat cells a major band for pRB was observed. A less pronounced band was seen in proliferating Jurkat cells ( Figure 2a ). In all cases, the immunoprecipitated pRB band corresponds to the hypophosphorylated form. No band was observed for Ki-67. Additionally, when using the anti-Ki-67 as the precipitating mAb, no band for pRB or ICBP90 was detected in the immunoprecipitates (data not illustrated), showing that the immunoprecipitation with the anti-ICBP90 mAb and the anti-pRB mAb were specific. To confirm the interaction between ICBP90 and the hypophosphorylated form of pRB, we performed similar experiments but inverted the mAbs, that is, the immunoprecipitating mAb was the anti-pRB and the anti-ICBP90 mAb was used for Western blotting. Under these conditions, no band was observed for Ki-67 either in fibroblasts or in Jurkat cells at confluence or in proliferation ( Figure 2b ). Both bands were observed for pRB showing that the anti-pRB mAb precipitated the inactive and active forms of pRB. Slight bands of ICBP90 were observed in proliferating cells, whereas at confluence, a major band was observed only for Jurkat cells (Figure 2b ). This result shows that the ICBP90/ pRB interaction to occur in a cell requires that this latter is proliferating or has cancerous features.
Further experiments were carried out on human lung fibroblasts in order to check whether pRB and ICBP90 may interact in late G1. Therefore, we synchronized fibroblasts with different drugs to block cells in G1, S and G2/M phases. Figure 3a shows that fibroblasts treated with mimosine, aphidicolin and nocadazole express both forms of pRB with a more pronounced effect with mimosine than with aphidicolin or nocadozale ( Figure 3a ). Interestingly, the highest level of ICBP90 was also observed in the presence of mimosine when compared to the other cell cycle blockers ( Figure 3a) . Control cells at confluence still show weak ICBP90 expression, due to the fact that the cells were harvested at the beginning of confluence (Figure 3a ), whereas after 24 h of confluence, no ICBP90 expression was detected (Figure 2) . Together, these results show Figure 2 Co-immunoprecipitation of ICBP90 and pRB in fibroblasts and Jurkat cells. Immunoprecipitations were performed on whole fibroblasts and Jurkat cell extracts with 5 mg/ml of anti-ICBP90 (a) and with 5 mg/ml of anti-pRB (b) followed by immunoblotting. Western blot analysis was performed with 1 mg/ml of anti-ICBP90, with 2 mg/ml of anti-pRB or with 2 mg/ml of antiKi-67. Fibroblasts and Jurkat cells were harvested after 24 h of confluence (C) or under proliferating conditions (P). The hyperand the hypophosphorylated forms of pRB are indicated by pp and p behind the arrowheads, respectively. Results are representative of four separate experiments ICBP90 regulates pRB expression M Jeanblanc et al that ICBP90 and both forms of pRB are expressed throughout the entire cell cycle and suggest a relationship between ICBP90 expression and pRB expression at the late G1 phase. Therefore, we blocked fibroblasts in late G1 by using mimosine and carried out GST pulldown assays (Figure 3b ). Purified fusion proteins GST-ICBP90 or GST-ICBP52 were incubated in the presence of nuclear extracts of synchronized human lung fibroblasts. Incubation with GST-ICBP90, but not with GST-ICBP52, showed binding of pRB (Figure 3b) . It was the hypophosphorylated form of pRB that was pulled down when comparing with the nuclear extracts from mimosine-treated fibroblasts or with confluent fibroblasts (inputs, Figure 3b ). Similar results were obtained with nuclear extracts from nonsynchronized Jurkat cells (data not shown).
Immunocytochemistry was carried out on mimosinesynchronized fibroblasts (Figure 4 ). Control labeling was performed in the absence of the primary monoclonal anti-pRB and in the absence of the polyclonal anti-ICBP90. No labeling was detectable for each control (data not shown). ICBP90 has been localized in the entire nucleoplasm as does pRB. The merged picture shows that ICBP90 and pRB are in general colocalized in discrete regions on the nucleus. However, the merged picture shows that in some cells the interaction between pRB and ICBP90 is a highly occurring event.
ICBP90 regulates pRB expression in human lung fibroblasts
In order to show whether ICBP90 could be a transcriptional regulator of the RB1 gene, we studied the effect of ICBP90 overexpression by using the pSG5/ICBP90 plasmid. A dose-dependent decrease of the pRB expression between 0.5 and 3 mg pSG5/ICBP90 was observed, whereas actin expression was not affected (Figure 5a ). Reverse transcription-polymerase chain reaction (RT-PCR) analysis of the RB1 mRNA level showed that overexpressing ICBP90 led to a decrease of the RB1 mRNA (Figure 5b ).
We performed DNA chromatin immunoprecipitation (ChIP) experiments to see if ICBP90 is interacting with the RB1 gene promoter during the cell cycle and to determine when it might occur ( Figure 6 ). For this, cells were synchronized with mimosine, aphidicolin and nocadozole to obtain G1, S and G2/M phases arrested fibroblasts (Figure 6a ). The synchronization of human fibroblasts in each phase was controlled by flow cytometry analysis (not illustrated) and were in accordance with one of our previous study (Mousli et al., 2003) . The treatment of fibroblasts with the drugs did not alter the PCR reaction on genomic DNA (Input) as compared with the control (C). The absence of immunoprecipitating Ab (C1) or the use of the antiKi-67 mAb (C2) did not reveal the presence of the RB1 gene promoter in the precipitate (Figure 6a ). However, when using the anti-ICBP90 mAb, a 342 bp long PCR fragment could be amplified in nonsynchronized fibroblasts (C). This amplification was also observed in mimosine-synchronized fibroblasts but not in aphidicolin-or nocodazole-treated cells (Figure 6a ), suggesting that ICBP90 only interacts with the RB1 gene promoter in late G1.
The cells were treated with 5-azacytidine (5-AZA) to demethylate DNA (Christman, 2002 ) and thus we investigated whether ICBP90 is still able to bind to the unmethylated RB1 gene promoter. Treatment of fibroblasts with 5-AZA led to a dose-dependent inhibition of Figure 3 (a) Expression of pRB and ICBP90 in synchronized human lung fibroblasts. Human lung fibroblasts were treated by L-mimosine (100 mg/ml), aphidicolin (1 mg/ml) or nocodazole (50 ng/ml) for 20 h. Control cells were cultured to obtain the beginning of confluence (Conf) or proliferating conditions (Prol), that is, at 50% confluence at the time when the treated cells were collected. Western blot analysis was performed with 1 mg/ml of anti-ICBP90, with 2 mg/ml of anti-pRB or with 1 mg/ml of anti-actin as control. The hyper-and the hypophosphorylated forms of pRB are indicated by pp and p behind the arrow heads, respectively. The Western blot is representative of three independent experiments. (b) GST pull-down assay were performed with nuclear extracts (250 mg) prepared from confluent culture of human lung fibroblasts synchronized in late G1 by treating cells with 100 mg/ml of mimosine for 20 h. Extracts were incubated with either sepharosebound GST-ICBP90 (2 mg), GST-RCP52 (2 mg) or GST alone (negative control). Bound proteins were released and probed for the presence of pRB by immunoblotting. Representative of five separate experiments Figure 4 Co-localization of ICBP90 and pRB in human lung fibroblasts synchronized in late G1 phase with mimosine. Cells were treated with 100 mg/ml of mimosine for 20 h. Immunocytochemistry was performed with anti-ICBP90 (1.25 mg/ml) and anti-pRB (10 mg/ml) and revealed with secondary Abs coupled to FITC (green) and Alexa488 (red), respectively. Representative of three separate experiments ICBP90 regulates pRB expression M Jeanblanc et al pRB expression between 3 and 60 mM (Figure 6b) . A nearly complete disappearance of pRB occurred with 100 mM 5-AZA. Similarly, ICBP90 also disappeared at 100 mM 5-AZA, but other concentrations had no effect except at 3 mM that surprisingly decreased ICBP90 expression (Figure 6b ). We have no explanation for the moment, but one might imagine that 3 mM of 5-AZA is a concentration that decreases the ICBP90 gene promoter activity directly or via the promoter activity of a transcription factor involved in the ICBP90 transcriptional regulation. It is important to notice that the decrease in ICBP90 expression at 3 mM of 5-AZA is accompanied by an increase in the pRB expression. DNA ChIP experiments were carried out without the concentration of 100 mM as no ICBP90 expression occurs at this concentration. Treatment of fibroblasts with various concentrations of 5-AZA, hindered dose dependently between 0 and 30 mM, to recover the RB1 gene promoter after immunoprecipitation with anti-ICBP90 (Figure 6c ). The treatment itself was without effect on the PCR performance (see input). This result suggests that ICBP90 is able to interact with the RB1 gene promoter only under its methylated form.
Overexpression of ICBP90 allows fibroblasts to re-enter cell cycle Figure 7 shows the effect of ICBP90 over-expression in serum starved human lung fibroblasts on the cell cycle phase, as assessed by flow cytometry analysis, and on the topoisomerase IIa expression. In pSG5/ICBP90-transfected fibroblasts, there was 44.0, 24.7 and 31.3% of the cells in G0/G1, S and G2/M phases, whereas in control fibroblasts, there was 90.7, 3.6 and 5.7% of the cells in G0/G1, S and G2/M phases, respectively (Figure 7a ). These results were confirmed by investigating the expression of topoisomerase IIa, a marker of proliferation, that is, of the S and G2/M phases . After 24 h, overexpression of ICBP90 in serum-starved lung fibroblasts enhanced topoisomerase IIa expression with an increase of 148.2% (Figure 7b ), as quantified on scanned blots with the NIH Image 1.62 software (National Institutes of Figure 5 Analysis of pRB expression after overexpression of ICBP90 in human lung fibroblasts. (a) Fibroblasts at 50% confluence were transfected with 3 mg of the pSG5 vector alone or with 0.5, 1.5 and 3 mg of the pSG5/ICBP90 construction by using FuGENE6 TM transfection reagent. Control (C) corresponds to fibroblasts treated with FuGENE6 TM alone. After transfection, cells were cultured for 24 h in media containing 10% FCS and cell lysates were prepared for analysis of ICBP90 and pRB expression by Western blot. Western blot analysis was performed with 1 mg/ml of anti-ICBP90, with 1 mg/ml of anti-pRB or with 1 mg/ml of antiactin. (b) After transfection of human lung fibroblasts with pSG5 (3 mg) or pSG5/ICBP90 (3 mg P/I) vectors, total RNA were extracted and reverse transcribed as described in the 'Materials and methods' section. PCR were finally performed to amplify pRB and GAPDH (control) cDNAs that were analysed on agarose gel. The size of amplified fragments of pRB and GAPDH cDNAs, respectively, is indicated by 342 and 240 bp Figure 6 Binding of ICBP90 to the RB1 gene promoter. (a) Chromatin was purified in the absence of drug (C) or after synchronization of fibroblast lung cell with 100 mg/ml mimosine (M), 1 mg/ml aphidicolin (A) and of 50 ng/ml nocodazole (N). Chromatin was then precipitated by using the ICBP90 mAb (5 mg), forehand fixed on protein A resin. One control was performed in the absence of antibody (0), whereas the other control (Ki-67) was performed in the presence of 5 mg/ml of anti-Ki-67. Health, Bethesda, MD, USA), suggesting that there are more cells in S and/or G2/M phases. This effect was accompanied by an increase of 21.7% in the cell number (data not shown).
Discussion
Several reasons led us to consider that ICBP90 may target pRB at the protein level as well as the transcriptional level as it was reported for the E3-ligase BRCA1 (Fan et al., 2001) . The presence in the ICBP90 protein sequence of pRB consensus binding sites combined with the expression patterns of ICBP90 and pRB that both peak in late G1 (Figure 3) suggest that a pRB/ICBP90 interaction participates in the regulation of the G1/S transition. Np95, which is a protein exhibiting high homology with ICBP90, has also been proposed to play an important role during the G1/S transition (Bonapace et al., 2002; Muto et al., 2002) . Previous studies reported little variations of pRB expression during the cell cycle when compared to the other members of the pRB-family proteins, that is, pRB2/p130 and p107 (Grana et al., 1998) . However, it can be observed in serum-starved WI38 cells (noncancer human lung fibroblasts) that 6 h serum treatment induced an increase in the hypophosphorylated form of pRB, followed by a downregulation 12 h later as the percentage of cells in S phase increased (Bhattacharya et al., 2003) .
The present study allowed us to show that in normal lung fibroblasts and in Jurkat cells ICBP90 interacts with the hypophosphorylated form of pRB. Strikingly, the most pronounced interaction was observed in Jurkat cells at confluence. From this, the idea that the interaction between ICBP90 and pRB at confluence is a physiopathological event occurring in cancer cells is emerging. This interaction may subsequently alter cellular functions, for example, p53-dependent mechanisms, considering that ICBP90 overexpression in human lung fibroblasts overcomes cell contact inhibition . Consistently with this, it was observed that p53 is involved in density-dependent growth arrest (Meerson et al., 2004) and in the downregulation of ICBP90 (Arima et al., 2004) . We do not yet know whether the consensus motif LXCXE of the RING finger is involved, but that of the PHD can be ruled out since ICBP52 cannot bind pRB. The consensus motif is not required in BRCA1 to interact with pRB, whereas the RING finger is (Fan et al., 2001 ). Accordingly, it was shown that pRB can exert its growth arrest property independently upon binding with LXCXE motifs (Chan et al., 2001) . Thus, it is rather the RING finger of ICBP90 than the consensus binding site that is involved. If so, this would mean that pRB can also interact with NIRF, although the consensus binding motif in the RING finger is lacking.
Physiologically, the pRB/ICBP90 interaction may contribute to decrease pRB levels as cells enter the S phase since pRB levels are lower in aphidicolinblocked cells than in mimosine-blocked cells (Figure 3 ) and ICBP90-siRNAs inhibited S-phase entry of HCT-116 cells (Arima et al., 2004) . Therefore, ICBP90 might be involved in the degradation of pRB probably via the proteasome pathway since ICBP90 belongs to a family of E3 ligase (Mousli et al., 2003) . The RING finger of Np95 is the domain that contains the E3 ligase that accepts the histone H3 as the substrate (Citterio et al., 2004) . Thus, reciprocally hypophosphorylated pRB when interacting with ICBP90 may modulate its E3 ligase activity and may alter ubiquitination of histone H3 and consequently gene transcription. Therefore, pRB degradation and/or phosphorylation would facilitate histone H3 ubiquitination by ICBP90, thus Figure 7 Effect of ICBP90 overexpression on the cell cycle phases of serum-deprived human fibroblasts. (a) Cells were deprived in serum for 24 h. Control fibroblasts were handled as for the transfected cells but without FuGENE6t. Cells were transfected for 24 h with pSG5 or pSG5/ICBP90 plasmids (6 mg). After then, cells were labeled with propidium iodide and analysed by flow cytometry. Columns correspond to the percentage of cells in each cell cycle phase obtained from three independent experiments performed in duplicate. Data were analysed with Student's t-test (**Po0.01). (b) Western blot analysis of ICBP90, topoisomerase IIa (TopoIIa) and actin expressions in serum-deprived human lung fibroblasts. Cells were deprived in serum for 24 h before transfection with pSG5 (6 mg) or with pSG5/ICBP90 (6 mg). Protein expression was analysed 24 h later. The blots were probed with Ki-S1 mAb (0.1 mg/ml), the anti-ICBP90 mAb (0.5 mg/ml) or with the polyclonal anti-actin antibody (0.8 mg/ml). Data are representative of three independent experiments ICBP90 regulates pRB expression M Jeanblanc et al favoring gene expression and cell entry into the S phase. Another putative role for the interaction of ICBP90 with pRB is the repression of genes. Indeed, it was shown in fibroblasts that pRB targets histone H3 methylation and HP1 to promoters of euchromatic genes by associating pRB with the histone methylase SUV39H1 and HP1 (Nielsen et al., 2001 ). SUV39H1 and HDAC1 was found in the same complex as pRB2 for repressing the estrogen receptor gene (Macaluso et al., 2003) . Interestingly, Np95 ubiquitinates histone H3 (Citterio et al., 2004) , whereas it was reported that ICBP90 cooperates with HDAC1 (Unoki et al., 2004) . Hence, we propose that ICBP90 is the protein that brings the pRB/SUV39H1/ HP1 complex and probably HDAC1 to the promoter of the corresponding genes.
Regarding the transcriptional regulation of pRB by ICBP90, we observed in human lung fibroblasts that overexpression of ICBP90 induced a downregulation of the RB1 mRNA accompanied by a decrease in the pRB expression. We could not overexpress ICBP90 in Jurkat cells for a yet undetermined reason. Consistent with our results, it was reported that overexpression of BRCA1 caused a downregulation of pRB but failed to induce growth arrest (Fan et al., 2001) . Interestingly, the binding of ICBP90 to the RB1 gene promoter occurs in the G1 phase and requires a methylation status, which is consistent with favoring entry into the S phase. The determination of ICBP90 functional binding sites on the RB1 gene promoter and of the extent of methylation necessary would be interesting to be approached. In the presence of 30 and 60 mM of 5-AZA, ICBP90 does not bind to the RB1 gene promoter but pRB expression is downregulated (Figure 6 ), suggesting that the interaction between pRB and ICBP90 is the complementary pathway to the transcriptional downregulation of pRB. We are currently investigating the experimental conditions in order to determine the contribution of each mechanism.
In yeast Bre1, also an E3 ligase, was found in a complex with Rad6 and this presence is required for H2B ubiquitination, which in turns seems to be a signal for H3 methylation (Wood et al., 2003) . Considering that Np95 ubiquitinates histone H3 (Citterio et al., 2004) , it was suggested that methylated DNA twisted around histone H3 might be the target of ICBP90 (Unoki et al., 2004) . Therefore, it is possible that H2B ubiquitination allows DNA methylation with subsequently binding of ICBP90, inducing then H3 methylation and/or ubiquitination, which in turn provokes additional DNA methylation. This is a scheme where ICBP90 exerts its repression effects by also recruiting HDAC1 (Unoki et al., 2004) . However, we do not exclude that ICBP90 also participate in gene upregulation considering that it increases topoisomerase IIa gene expression and that ICBP90 interacts with Tip60, an histone acetylase (Hopfner et al., 2000; Bronner et al., 2002) .
In conclusion, we found that (i) ICBP90 and pRB physically interacts in vivo in late G1, (ii) ICBP90 binds to the methylated RB1 gene promoter in the G1 phase, and (iii) these two combined effects of ICBP90 allows cells to enter the S phase. Furthermore, we propose that deregulation of ICBP90 in cancer cells alter the pRB functions and thus being a mechanism involved in cancerogenesis.
Materials and methods
Chemicals and antibodies
The mouse monoclonal antibody (clone 1RC1C-10) raised against ICBP90 was engineered as described elsewhere (Hopfner et al., 2000) . Horseradish peroxidase-conjugated anti-mouse antibodies (for mAbs), horseradish peroxidaseconjugated anti-rabbit antibodies (for polyclonal antibodies), Tween s 20, the protease inhibitor cocktail and the antitopoisomerase IIa mAb (Ki-S1) were purchased from Roche Diagnostics (Mannheim, Germany). The anti-Ki-67 (clone Mib-1) antibody was obtained from Dako SA (Trappes, France). Aphidicolin, L-mimosine, nocodazole, 5-AZA, propidium iodide and the rabbit anti-actin antibody were obtained from Sigma Chemicals (St Louis, MO, USA) and the mouse anti-pRB mAb (clone MAB3186) from Chemicon International (Temecula, CA, USA). The ECL detection system was obtained from (Amersham Biosciences Europe Gmbh, Saclay, France).
Cell cultures and cell synchronization
Human lung fibroblasts in primary culture were prepared and cultured as described elsewhere (Hopfner et al, 2000) . The human T-lymphocyte cell line Jurkat was obtained from the America Type Culture Collection (Mannassa, VA, USA) and was grown in RPMI 1640 supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin and 50 mg/ml streptomycin. To synchronize fibroblasts, cells were treated with L-mimosine (100 mg/ml), aphidicolin (1 mg/ml) or nocodazole (50 ng/ml) for 20 h to arrest cells in the G1, S or in the G2/M phases, respectively (Cheng and Kuchta, 1993; Vasquez et al., 1997; Wang et al., 2000) .
Flow cytometry
Cell suspensions were fixed by incubation for 15 min on ice with 5% formaldehyde in PBS (vol/vol), followed by resuspension in 5 ml of ethanol and storage at À201C for 16 h. DNA labeling was obtained by incubation for 10 h at 201C in darkness with 50 mg/ml of propidium iodide and 50 mg/ml of RNAse A. Experiments were performed with 30 000 cells. The DNA contents were quantified with a FACScan flow cytometer and data were analysed with the CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA).
Western blotting
Whole-cell extract preparations were described elsewhere (Hopfner et al., 2000) . Blots were probed with either the anti-ICBP90 mAb (0.5 mg/ml), the anti-pRB (2 mg/ml) or the anti-actin Ab (1 mg/ml). Secondary peroxidase-conjugated antibodies were used at 200 mU/ml. Signals were detected by chemiluminescence using the ECL detection system.
Immunocytochemistry
Immunofluorescence staining of human lung fibroblasts were carried out as described elsewhere (Hopfner et al., 2000) . Briefly, primary human fibroblasts were seeded at 15 000 cells/ cm 2 and cultured on sterile coverslips in 24-well dishes during 2 ICBP90 regulates pRB expression M Jeanblanc et al days in 1 ml of culture medium. Cells were first incubated with 1 mg/ml of a purified polyclonal anti-ICBP90 (engineered in our core facilities) in PBS, supplemented with 1% bovine serum albumin for 2 h, washed and incubated with secondary anti-rabbit antibodies conjugated with Alexa488-Fluor (Molecular Probes) during 30 min. Cells were incubated with antipRB mAb (1 mg/ml) overnight at room temperature in the same buffer followed by two washes. Fixed anti-pRB mAb was revealed by sequentially using a biotinylated anti-mouse Ab and cyanine 3-conjugated extravidin. After three washes with PBS, the coverslips were mounted on slides with Mowiol (Calbiochem Merck Eurolab, Fontenay-sous-Bois, France) and observed under epifluorescence.
Pull-down assays and co-immunoprecipitation
GST-ICBP90 fusion protein was obtained by cloning the ICBP90 cDNA (Genbank Accession number AF129507) into the pGEX4T1 vector (Amersham Biosciences Europe Gmbh) as described elsewhere (Hopfner et al., 2000) . GST-ICBP52 is a fusion protein obtained by cloning into the pGEX4T1 vector a partial cDNA of ICBP90 (amino acids 263-695) obtained by screening the Jurkat cDNA library in the one-hybrid system (Hopfner et al., 2000) . For in vivo pull-down assays, the indicated GST-ICBP90 and GST-ICBP52 fusion proteins were overexpressed in Escherichia coli (XL1 Blue) and subsequently purified by using glutathione-sepharose beads (Amersham Biosciences Europe Gmbh). In all, 2 mg of each fusion protein and GST alone coupled to glutathione-sepharose beads were incubated for 2 h at 41C with 250 mg of nuclear extracts prepared from human lung fibroblasts in pull-down buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% Nonidet P-40, 1 mM DTT) and proteases inhibitors cocktail (one tablet for 10 ml of buffer). After five washes, bound proteins were eluted and separated on 8% acrylamide SDS/PAGE gels, blotted and probed with the antipRB mAb (2 mg/ml).
For co-immunoprecipitation of pRB and ICBP90, 500 mg of Jurkat and human lung fibroblasts whole-cell extracts were incubated with protein G beads coupled to either anti-ICBP90, anti-pRB or anti-Ki-67 (negative control) in PBS supplemented with proteases inhibitors for 2 h at 41C. Beads were washed five times in 1 ml of PBS and bound proteins were removed from the beads and denatured by Laemmli solution and separated on 6% acrylamide SDS/PAGE gels, blotted and finally probed with anti-ICBP90 (1 mg/ml) or anti-pRB (2 mg/ml) or anti-Ki-67 (2 mg/ml).
Reverse transcription-polymerase chain reaction
Total RNA was isolated by a Rneasy Mini Qiagen Kit (Courtaboeuf, France) and quantified by spectrophotometry. Total RNA (1 mg) was reverse transcribed using M-MLV Reverse Transcriptase (Promega, Charbonnie`res, France). The PCR reaction was carried out according to the manufacturer's instructions (Perkin-Elmer Cetus, USA). Briefly, 50 ml of a reaction mixture including 2 U of Taq polymerase (Promega), 5 ml of 10 Â buffer, 1.5 mM MgCl 2 , 100 mM dNTPs, 2 ml of firststrand cDNA and 20 pmol of each primer, was subjected to 35 PCR cycles. The following primer pairs were used for PCR amplification: (1) GAPDH (sense: 5 0 -GGTGAAGGTCGG AGTCAACGGA-3 0 ; antisense: 5 0 -GAGGGATCTCGCTCC TGGAAGA-3 0 ); and (2) Rb (sense: 5 0 -CTAGATGAGATG TCGTTCACTT-3 0 ; antisense: 5 0 -AAGGACACATAGCATT AACTGA-3 0 ).
ChIP assay
Human lung fibroblast cells (2 Â 10 6 cells) were fixed with 1% formaldehyde for 10 min. Formaldehyde was neutralized by incubation with 125 mM glycine for 10 min and then washed twice with ice-cold PBS. Cells were lysed for 5 min on ice in 500 ml of buffer containing 50 mM Tris, pH 8.0, 2 mM EDTA, 0.1% NP-40, 10% glycerol. Nuclei were centrifuged at 1600 g for 3 min and resuspended in 200 ml of 50 mM Tris, pH 8.0, 5 mM EDTA, 1% SDS (supplemented with proteases inhibitors), and subsequently sonicated five times for 5 s. The nuclei preparations were cleared by centrifugation and diluted 10 times in 50 mM Tris, pH 8.0, 0.5 mM EDTA, 0.5% NP-40 and 0.2 M NaCl. Extracts were precleared for 2 h with 60 ml of a 50% suspension of salmon sperm DNA-treated protein A-Agarose beads (Upstate, Charlottesville, VA, USA). An aliquot of precleared chromatin was removed, heat treated to reverse protein-DNA interaction and precipitated with isopropanol (referred as input before immunoprecipitation). The remainder of chromatin sample was preincubated overnight at 41C either with 10 mg of anti-ICBP90 or irrelevant mouse Ab (negative control), and further incubated for 2 h with 40 ml of 50% protein A-Agarose beads. The beads were washed five times with 1 ml of wash buffer (20 mM Tris, pH 8.0, 0.1% SDS, 2 mM EDTA, 1% NP-40 and 0.15 M NaCl) and three times with 10 mM Tris, pH 8.0, 1 mM EDTA. Protein-DNA complexes were eluted by three successive treatments with 150 ml of 1% SDS and 100 mM NaHCO 3 . NaCl was then adjusted to 0.3 M and 1 ml of RNAse A (10 mg/ml) was added. Protein-DNA crosslinks were reversed by heating at 651C overnight, and DNA was extracted by adding 20 ml of 1 M Tris, pH 7.5, 10 ml of 0.5 M EDTA and 2 ml of proteinase K (20 mg/ml) at 501C for 30 min. After phenol/chloroform extraction and isopropanol co-precipitation with 30 mg of glycogen, the pellet was resuspended in 30 ml of Tris-EDTA. For the duplex PCR reaction, 2 ml of ChIP DNA was used as template in a total volume of 25 ml PCR buffer containing 20 pmol of each primer for RB1 gene promoter, corresponding to the promoter sequence. Sense primer was 5 0 -CACAGCTCCCTCCCTTCC TTTC-3 0 and the antisense primer was 5 0 -CTACCCAGAACC ACCCCCTCCA-3 0 (see positions in the promoter in Figure 1a ).
